{"gene":"PFKFB4","run_date":"2026-04-28T19:45:44","timeline":{"discoveries":[{"year":2018,"finding":"PFKFB4 phosphorylates the transcriptional coactivator SRC-3 at serine 857, enhancing SRC-3 transcriptional activity. Phospho-Ser857 SRC-3 increases its interaction with transcription factor ATF4, stabilizing recruitment of SRC-3 and ATF4 to target gene promoters. This drives glucose flux toward the pentose phosphate pathway and enables purine synthesis by transcriptionally upregulating transketolase, AMPD1, and XDH.","method":"Kinome-wide RNAi screen, in vitro kinase assay, phosphorylation-deficient mutant (Ser857Ala), Co-IP, ChIP, orthotopic xenograft mouse model","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including in vitro kinase assay, mutagenesis, Co-IP, ChIP, and in vivo validation in a single rigorous study","pmids":["29615789"],"is_preprint":false},{"year":2014,"finding":"Recombinant human PFKFB4 exhibits kinase activity 4.3-fold greater than its phosphatase activity, functioning primarily to synthesize fructose-2,6-bisphosphate (F2,6BP), which allosterically activates PFK-1 to increase glycolytic flux. siRNA and genomic deletion of PFKFB4 decrease F2,6BP levels, while overexpression increases them.","method":"In vitro enzymatic assay with recombinant human PFKFB4, siRNA knockdown, genomic deletion, metabolite measurement (F2,6BP, glucose uptake, ATP)","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro kinase/phosphatase assay with recombinant protein, corroborated by genetic loss- and gain-of-function","pmids":["25115398"],"is_preprint":false},{"year":2015,"finding":"A first-in-class PFKFB4 inhibitor (5MPN), identified by structure-based virtual screening, selectively inhibits PFKFB4 kinase activity, suppresses intracellular F2,6BP synthesis, reduces glycolysis, and inhibits tumor growth in mice upon oral administration.","method":"Structure-based virtual computational screening, in vitro enzyme inhibition assay, cell proliferation assays, in vivo xenograft mouse model","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 1-2 — structure-guided inhibitor design with in vitro enzymatic validation and in vivo efficacy","pmids":["26221874"],"is_preprint":false},{"year":2015,"finding":"In Xenopus (frog) embryos, PFKFB4 controls dorsal ectoderm patterning and progenitor differentiation via a non-glycolytic function mediated by AKT signaling. Restoring AKT signaling rescues the PFKFB4 loss-of-function phenotype, while glycolysis inhibition does not recapitulate the patterning defects.","method":"Loss-of-function morpholino depletion in Xenopus embryos, epistasis rescue with constitutively active AKT, glycolysis inhibitors as controls","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in vivo with multiple rescue conditions demonstrating AKT dependence and glycolysis independence","pmids":["25601028"],"is_preprint":false},{"year":2017,"finding":"PFKFB4 is essential for neural crest (NC) specification and migration in Xenopus embryos. PFKFB4 controls AKT signaling during late NC specification, while both AKT signaling and glycolysis regulate NC migration. NC gene regulatory network drives pfkfb4 upregulation during NC specification.","method":"Time-controlled and hypomorph depletions in vivo (Xenopus), AKT signaling rescue, glycolysis inhibition experiments","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with multiple conditions, in vivo phenotypic rescue","pmids":["29038306"],"is_preprint":false},{"year":2017,"finding":"Etk (BMX) tyrosine kinase directly interacts with PFKFB4 (identified by co-IP and GST pulldown), and PFKFB4 is a downstream target of Etk that promotes chemoresistance in small-cell lung cancer through regulation of autophagy.","method":"Co-immunoprecipitation, GST pulldown, microarray analysis, gain/loss-of-function in vitro and in vivo, PDX model","journal":"Clinical Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal co-IP and GST pulldown confirm direct interaction; functional link to autophagy established","pmids":["29208667"],"is_preprint":false},{"year":2022,"finding":"PIM2 kinase phosphorylates PFKFB4 at threonine 140 (Thr140), enhancing PFKFB4 protein stability via the ubiquitin-proteasome pathway and promoting glycolysis and cell growth in endometriosis. PIM2 was identified as a binding partner of PFKFB4.","method":"Co-IP, biochemical phosphorylation assays, ubiquitin-proteasome pathway analysis, in vivo endometriosis model","journal":"Cell Death & Disease","confidence":"Medium","confidence_rationale":"Tier 2 — site-specific phosphorylation identified biochemically with functional validation","pmids":["36109523"],"is_preprint":false},{"year":2022,"finding":"PFKFB4 interacts with the E3 ubiquitin ligase FBXO28, and this interaction regulates ubiquitylation and proteasomal degradation of HIF-1α in glioblastoma. PFKFB4 silencing dramatically reduces HIF protein levels and hypoxia-related gene expression.","method":"Mass spectrometric analysis of immunoprecipitated PFKFB4 (identifying FBXO28), Western blot, gene expression profiling, orthotopic patient-derived mouse model","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2 — MS-identified interaction partner with functional validation of HIF-1α ubiquitination","pmids":["36115843"],"is_preprint":false},{"year":2022,"finding":"PFKFB4 interacts with ICMT (a posttranslational modifier of RAS), promotes ICMT/RAS interaction, controls RAS localization at the plasma membrane, activates AKT signaling, and enhances melanoma cell migration independently of glycolysis.","method":"Co-IP, RAS localization imaging, AKT signaling assays, migration assays with PFKFB4 loss-of-function","journal":"Life Science Alliance","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP demonstrating interaction, supported by functional rescue experiments and localization data","pmids":["35914811"],"is_preprint":false},{"year":2021,"finding":"PFKFB4 phosphorylates NCOA3 (SRC-3/AIB1) in clear-cell renal cell carcinoma, and this phosphorylated NCOA3 interacts with FBP1 to counteract overactive pentose phosphate pathway flux, forming a regulatory loop. PFKFB4 also promotes the pentose phosphate pathway in ccRCC.","method":"Phosphoproteomics, immunoprecipitation, metabolomics, CRISPR/Cas9 knockout","journal":"Journal of Experimental & Clinical Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 — phosphoproteomics and immunoprecipitation with metabolomic validation","pmids":["34593007"],"is_preprint":false},{"year":2021,"finding":"PFKFB4 promotes lung adenocarcinoma progression by phosphorylating SRC-2 (steroid receptor coactivator-2) at Ser487, altering its transcriptional activity, which transcriptionally upregulates CARM1.","method":"Co-immunoprecipitation, Western blot for phosphorylation, PFKFB4 knockdown, transcriptome sequencing","journal":"BMC Pulmonary Medicine","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP and phosphorylation analysis with downstream transcriptome validation","pmids":["33593309"],"is_preprint":false},{"year":2022,"finding":"PFKFB4 promotes breast cancer metastasis via induction of HAS2 expression and hyaluronan (HA) production in a p38 signaling-dependent manner. PFKFB4 loss-of-function reduces HAS2 mRNA/protein and HA secretion.","method":"Gain- and loss-of-function assays, ELISA, immunofluorescence, orthotopic xenograft, experimental metastasis model","journal":"Cellular Physiology and Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro and in vivo functional studies with defined downstream pathway (p38/HAS2)","pmids":["30415245"],"is_preprint":false},{"year":2022,"finding":"Hypoxic induction of PFKFB4 triggers its nuclear translocation, where it non-canonically activates HIF-1α transcription, creating a feed-forward loop. Breast cancer patients with increased nuclear PFKFB4 correlate with poor prognosis.","method":"Photoacoustic imaging, metabolomics, genetic ablation in mouse models, nuclear fractionation/immunofluorescence localization, gene expression analysis","journal":"Cell Reports","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization experiment (nuclear translocation) linked to functional consequence (HIF-1α activation), supported by in vivo genetic ablation","pmids":["36476868"],"is_preprint":false},{"year":2023,"finding":"FBXL7 (an E3 ubiquitin ligase) ubiquitinates and degrades PFKFB4 protein, suppressing glucose metabolism. Hypoxia-induced HIF-1α upregulates EZH2, which represses FBXL7 transcription, thereby stabilizing PFKFB4 and promoting glycolysis in NSCLC. PFKFB4 was identified as an FBXL7 substrate by tandem affinity purification/mass spectrometry.","method":"Tandem affinity purification coupled with mass spectrometry (TAP/MS), ubiquitination assay, ChIP, loss-of-function, rescue experiments","journal":"Cell Death & Disease","confidence":"Medium","confidence_rationale":"Tier 2 — substrate identified by TAP/MS with functional ubiquitination validation","pmids":["37179372"],"is_preprint":false},{"year":2023,"finding":"THOC3 forms a complex with YBX1 to promote PFKFB4 transcription and is responsible for exporting PFKFB4 mRNA to the cytoplasm; YBX1 ensures stability of PFKFB4 mRNA by recognizing m5C sites in its 3'UTR.","method":"Co-IP, mRNA export assays, YBX1-m5C binding analysis, knockdown functional assays","journal":"Cell Death & Disease","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP for complex formation with mechanistic mRNA regulation assays","pmids":["37500615"],"is_preprint":false},{"year":2016,"finding":"HIF-1α directly transactivates PFKFB4 expression in bladder cancer under hypoxia by binding to a specific hypoxia-responsive element (HRE-D) in the PFKFB4 promoter, as identified by deletion constructs and double-immunofluorescence co-localization.","method":"Promoter deletion/luciferase assays, ChIP, double-immunofluorescence co-localization, hypoxia exposure","journal":"Biochemical and Biophysical Research Communications","confidence":"Medium","confidence_rationale":"Tier 2 — promoter-reporter assays with mutagenesis identifying functional HRE, supported by ChIP","pmids":["27181362"],"is_preprint":false},{"year":2016,"finding":"Phosphorylation of PPARγ at Ser84 (by MEK/ERK) drives PFKFB4 expression by directly modulating its promoter transcriptional activity, as shown by ChIP. PFKFB4 is required for the PPARγ phosphorylation-mediated stimulation of glycolysis and proliferation in hepatocellular carcinoma.","method":"RNA microarray, ChIP assay, PFKFB4 knockdown rescue experiments, HCC mouse model","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP confirms direct promoter binding, PFKFB4 knockdown establishes epistasis","pmids":["27769068"],"is_preprint":false},{"year":2012,"finding":"Sertoli cell-secreted FGF-2 induces PFKFB4 expression in mouse spermatogenic cells via the MEK/ERK/CREB pathway. A CRE-binding sequence at -1,463 relative to the transcription start site is required for PFKFB4 gene activation. CREB transcription factor binding to this site was confirmed by pulldown assays.","method":"Conditioned medium experiments, MAPK inhibitor panel, luciferase analysis of promoter deletion constructs, CREB pulldown assay, anti-FGF-2 neutralizing antibodies","journal":"American Journal of Physiology – Endocrinology and Metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — promoter-reporter assays with mutagenesis and CREB pulldown identifying functional CRE site","pmids":["22811469"],"is_preprint":false},{"year":2021,"finding":"In hepatocellular carcinoma with TP53 loss-of-function mutations, PFKFB4 functions predominantly as a phosphatase (not kinase); its ablation causes accumulation of metabolites in downstream glycolysis and the pentose phosphate pathway, and also induces hypoxia-responsive genes in glycolysis and ROS detoxification.","method":"CRISPR/Cas9 knockout, targeted metabolomic profiling, RNA sequencing, in vivo HCC model","journal":"Cellular and Molecular Gastroenterology and Hepatology","confidence":"Medium","confidence_rationale":"Tier 2 — CRISPR KO with metabolomic profiling providing direct mechanistic evidence of phosphatase activity dominance in this context","pmids":["36806581"],"is_preprint":false},{"year":2025,"finding":"The E3 ubiquitin ligase CHIP directly binds and ubiquitinates PFKFB4 at lysine 305 (K305), promoting its proteasomal degradation and suppressing glycolysis and invasiveness in endometriosis cells.","method":"Co-IP, ubiquitination assay, site-directed mutagenesis (K305), in vitro and in vivo endometriosis models","journal":"Biology of Reproduction","confidence":"Medium","confidence_rationale":"Tier 2 — site-specific ubiquitination site identified by mutagenesis with functional validation","pmids":["40684802"],"is_preprint":false},{"year":2025,"finding":"A non-canonical splice variant of PFKFB4 (PFKFB4-ΔEx6, skipping exon 6, resulting in a 19-amino acid in-frame deletion) directly binds the kinase domain of AKT and activates AKT/mTOR signaling in hepatocellular carcinoma, promoting HCC proliferation and tumorigenicity more potently than canonical PFKFB4.","method":"Protein immunoprecipitation, in vitro kinase assay, Human Phospho-Kinase Array profiling, HCC cell line and xenograft models","journal":"JHEP Reports","confidence":"Medium","confidence_rationale":"Tier 1-2 — in vitro kinase assay and immunoprecipitation demonstrating direct binding to AKT kinase domain","pmids":["41281445"],"is_preprint":false},{"year":2021,"finding":"MLL (a histone methyltransferase/epigenetic regulator) promotes PFKFB4 expression at the transcriptional level through the putative E2F6 binding site in the pfkfb4 gene promoter in acute monocytic leukemia cells.","method":"ChIP, promoter analysis, PFKFB4 knockdown/inhibitor functional assays","journal":"Biochemical and Biophysical Research Communications","confidence":"Low","confidence_rationale":"Tier 3 — ChIP-based promoter analysis without full mechanistic dissection; single study","pmids":["32299611"],"is_preprint":false},{"year":2016,"finding":"PFKFB4-mediated glycolytic reprogramming activates pro-fibrotic TGFβ signaling in fibrous dysplasia. Depletion of PFKFB4 blocks fibrosis progression in GNAS(R201H)-mutated iPSC-derived mesenchymal stem cells.","method":"iPSC-derived FD disease models (2D and 3D), PFKFB4 depletion, glycolysis and TGFβ signaling inhibition experiments","journal":"Biomaterials","confidence":"Low","confidence_rationale":"Tier 3 — loss-of-function with pathway read-out, single study with no direct molecular mechanism for PFKFB4-TGFβ connection","pmids":["27614159"],"is_preprint":false},{"year":2021,"finding":"E2F2 transcriptionally activates PFKFB4 by directly binding to its promoter (shown by ChIP and luciferase assays), and PFKFB4 activates the PI3K/AKT pathway to promote glioma glycolysis and metastasis.","method":"ChIP, luciferase reporter assays, PFKFB4 knockdown rescue, PI3K/AKT pathway analysis","journal":"Life Sciences","confidence":"Low","confidence_rationale":"Tier 3 — ChIP and reporter assays; epistasis for PI3K/AKT activation is inferred rather than directly demonstrated","pmids":["33774025"],"is_preprint":false},{"year":2025,"finding":"PFKFB4 directly interacts with and phosphorylates HSPB1 (Heat Shock Protein Beta-1), suppressing ferroptosis and promoting gastric cancer progression. Pharmacological inhibition of PFKFB4 with 5MPN sensitizes gastric cancer cells to ferroptotic death.","method":"Co-IP, in vitro kinase assay (implied by 'direct interaction with and phosphorylation of HSPB1'), ferroptosis assays, 5MPN inhibitor treatment in vivo","journal":"Biochemical Pharmacology","confidence":"Low","confidence_rationale":"Tier 3 — single study; phosphorylation of HSPB1 described but full kinase assay methodology details limited in abstract","pmids":["41577048"],"is_preprint":false},{"year":2021,"finding":"CD44ICD (the cleaved intracellular domain of CD44) interacts with CREB and binds to the PFKFB4 promoter, thereby regulating PFKFB4 transcription and expression, which in turn facilitates glycolysis and promotes breast cancer stemness.","method":"ChIP (CD44ICD-CREB-PFKFB4 promoter binding), gain/loss-of-function, glycolysis assays, stemness assays, xenograft model","journal":"Theranostics","confidence":"Low","confidence_rationale":"Tier 3 — ChIP for promoter occupancy; PFKFB4 role downstream is established functionally but mechanism of PFKFB4 action not dissected","pmids":["30613295"],"is_preprint":false},{"year":2025,"finding":"In zebrafish larval xenografts, PFKFB4 depletion reduces invasion in MeWo melanoma cells (associated with reduced SNAIL2 expression) without affecting tumor growth, while in A375P cells it decreases tumor growth without affecting invasion—demonstrating context-dependent roles of PFKFB4 in melanoma progression.","method":"Zebrafish larval xenograft model, PFKFB4 depletion, SNAIL2 expression analysis, rescue experiments","journal":"bioRxiv (preprint)","confidence":"Low","confidence_rationale":"Tier 3 — in vivo loss-of-function in zebrafish model; preprint, single study","pmids":["bio_10.1101_2025.09.06.674616"],"is_preprint":true},{"year":2025,"finding":"PTBP1 lactylation (at K436) inhibits PTBP1 proteasomal degradation by attenuating its interaction with TRIM21, and lactylated PTBP1 enhances RNA-binding capacity and facilitates PFKFB4 mRNA stabilization, further increasing glycolysis in glioma stem cells. SIRT1 induces PTBP1 delactylation.","method":"Lactylation proteomics, co-IP, RNA-binding assays, PFKFB4 mRNA stability assays, PTBP1 K436 site-specific mutagenesis","journal":"Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 — site-specific lactylation mutagenesis with RNA-binding and protein stability functional validation","pmids":["39570804"],"is_preprint":false},{"year":2025,"finding":"PFKFB4 suppresses phosphorylated AMPK (p-AMPK) activity through enhanced aerobic glycolysis, which in turn stimulates SREBP1 expression, driving de novo lipid synthesis and promoting HCC proliferation.","method":"Functional assays (glycolysis and lipid synthesis), PFKFB4 knockdown/overexpression, AMPK and SREBP1 signaling pathway analysis","journal":"Cancer Letters","confidence":"Low","confidence_rationale":"Tier 3 — pathway inference from loss/gain-of-function without direct enzymatic demonstration of AMPK regulation","pmids":["40339954"],"is_preprint":false}],"current_model":"PFKFB4 is a bifunctional enzyme (primarily acting as a kinase, with ~4-fold greater kinase than phosphatase activity in most cancer contexts) that synthesizes fructose-2,6-bisphosphate to allosterically activate PFK-1 and increase glycolytic flux; beyond this canonical metabolic role, PFKFB4 functions as an atypical protein kinase that phosphorylates nuclear transcriptional coactivators SRC-3 (at Ser857, promoting ATF4 interaction and pentose phosphate pathway gene transcription) and SRC-2 (at Ser487), can translocate to the nucleus to non-canonically activate HIF-1α transcription, interacts with FBXO28 to regulate HIF-1α ubiquitination, interacts with ICMT to control RAS membrane localization and AKT signaling, is regulated post-translationally by PIM2-mediated phosphorylation (Thr140) and CHIP/FBXL7-mediated ubiquitination, and controls AKT signaling (partly independently of glycolysis) during embryonic patterning and neural crest development."},"narrative":{"teleology":[{"year":2012,"claim":"Identifying how PFKFB4 transcription is controlled established the FGF-2/MEK/ERK/CREB axis as an upstream activating pathway, with a functional CRE site at −1,463 in the promoter, linking extracellular growth factor signaling to glycolytic gene regulation in spermatogenic cells.","evidence":"Conditioned medium, MAPK inhibitor panel, promoter deletion/luciferase assays, and CREB pulldown in mouse spermatogenic cells","pmids":["22811469"],"confidence":"Medium","gaps":["Whether CREB-dependent activation operates in somatic/cancer cell contexts","No chromatin-level mechanism described"]},{"year":2014,"claim":"Resolving the long-debated kinase-versus-phosphatase balance for human PFKFB4 demonstrated that recombinant PFKFB4 functions primarily as a kinase (4.3-fold kinase > phosphatase), synthesizing F2,6BP to activate PFK-1 and glycolytic flux — establishing the canonical enzymatic function.","evidence":"In vitro enzymatic assay with recombinant protein, siRNA knockdown, genomic deletion, and F2,6BP/glucose/ATP measurement in cancer cells","pmids":["25115398"],"confidence":"High","gaps":["Whether kinase/phosphatase ratio varies across tissues or genetic backgrounds","No structural basis for the kinase-dominant activity"]},{"year":2015,"claim":"Discovery of a glycolysis-independent developmental role established that PFKFB4 controls dorsal ectoderm patterning via AKT signaling in Xenopus embryos, revealing that PFKFB4 has non-metabolic functions that cannot be explained by F2,6BP synthesis alone.","evidence":"Morpholino depletion in Xenopus embryos with epistasis rescue by constitutively active AKT; glycolysis inhibitors failed to phenocopy","pmids":["25601028"],"confidence":"High","gaps":["Molecular mechanism linking PFKFB4 to AKT activation unknown at this point","Whether the non-glycolytic function is conserved in mammals"]},{"year":2015,"claim":"Development of a first-in-class selective PFKFB4 kinase inhibitor (5MPN) provided pharmacological proof that PFKFB4 kinase activity drives F2,6BP production and tumor growth, and delivered a chemical tool for functional studies.","evidence":"Structure-based virtual screening, in vitro enzyme inhibition, and oral xenograft efficacy in mice","pmids":["26221874"],"confidence":"High","gaps":["Selectivity over other PFKFB family members not fully resolved","No co-crystal structure reported"]},{"year":2016,"claim":"Identification of HIF-1α binding to a specific HRE (HRE-D) in the PFKFB4 promoter, and separately of phospho-PPARγ-driven PFKFB4 transcription, established that multiple hypoxia and oncogenic transcription factors directly induce PFKFB4 expression, explaining its upregulation across diverse cancers.","evidence":"Promoter deletion/luciferase and ChIP in bladder cancer (HIF-1α); ChIP and knockdown rescue in HCC (PPARγ)","pmids":["27181362","27769068"],"confidence":"Medium","gaps":["How multiple transcription factors coordinate at the PFKFB4 promoter","Relative contribution of each factor in different tumor types unknown"]},{"year":2017,"claim":"Demonstrating that PFKFB4 is essential for neural crest specification and migration through AKT signaling extended the non-glycolytic paradigm to a specific developmental cell type, while showing that glycolysis is separately required for NC migration.","evidence":"Time-controlled and hypomorph depletions with AKT rescue and glycolysis inhibition in Xenopus NC cells","pmids":["29038306"],"confidence":"High","gaps":["Direct PFKFB4-AKT biochemical interaction not demonstrated in this system","Mammalian NC relevance untested"]},{"year":2017,"claim":"Identification of Etk/BMX tyrosine kinase as a direct PFKFB4-binding partner linked PFKFB4 to chemoresistance via autophagy regulation in small-cell lung cancer, broadening its signaling network beyond AKT.","evidence":"Reciprocal co-IP, GST pulldown, microarray, PDX model in SCLC","pmids":["29208667"],"confidence":"Medium","gaps":["Whether Etk phosphorylates PFKFB4 and at which site is unknown","Autophagy mechanism downstream of PFKFB4 not dissected"]},{"year":2018,"claim":"The pivotal discovery that PFKFB4 acts as an atypical protein kinase phosphorylating SRC-3 at Ser857 revealed a fundamentally new non-metabolic function: PFKFB4-mediated SRC-3 phosphorylation promotes SRC-3–ATF4 interaction, driving pentose phosphate pathway gene transcription and purine synthesis, thus redirecting glucose carbon beyond glycolysis.","evidence":"Kinome-wide RNAi screen, in vitro kinase assay, Ser857Ala mutagenesis, Co-IP, ChIP, orthotopic xenograft in breast cancer","pmids":["29615789"],"confidence":"High","gaps":["Structural basis for PFKFB4's protein kinase activity versus its metabolic kinase activity unknown","Whether PFKFB4 protein kinase activity uses the same active site as F6P phosphorylation"]},{"year":2021,"claim":"Extension of the atypical kinase paradigm showed PFKFB4 phosphorylates SRC-2 at Ser487 (upregulating CARM1 transcription) and that phospho-SRC-3 interacts with FBP1 to form a regulatory feedback loop controlling pentose phosphate pathway flux in ccRCC, demonstrating substrate diversification.","evidence":"Co-IP and phosphorylation analysis with transcriptome sequencing (SRC-2, lung adenocarcinoma); phosphoproteomics and metabolomics with CRISPR KO (SRC-3/FBP1, ccRCC)","pmids":["33593309","34593007"],"confidence":"Medium","gaps":["In vitro kinase assay for SRC-2 not explicitly shown","Whether SRC-2 and SRC-3 phosphorylation occur simultaneously in the same cells"]},{"year":2021,"claim":"Demonstration that PFKFB4 phosphatase activity predominates in TP53-mutant HCC — opposite to the canonical kinase-dominant model — revealed that the kinase/phosphatase balance is genetically context-dependent, with TP53 status switching PFKFB4's functional output.","evidence":"CRISPR/Cas9 knockout with targeted metabolomics and RNA-seq in TP53-mutant HCC","pmids":["36806581"],"confidence":"Medium","gaps":["Molecular mechanism by which p53 loss shifts kinase/phosphatase ratio unknown","Whether this applies to other p53-mutant cancer types"]},{"year":2022,"claim":"Three concurrent discoveries expanded PFKFB4's non-metabolic signaling network: (1) PFKFB4 interacts with FBXO28 to regulate HIF-1α ubiquitination and stability, (2) PFKFB4 interacts with ICMT to promote RAS membrane localization and AKT activation independently of glycolysis, and (3) PIM2 phosphorylates PFKFB4 at Thr140 to stabilize it against proteasomal degradation — collectively revealing PFKFB4 as a signaling hub regulated by and regulating multiple oncogenic pathways.","evidence":"MS-identified FBXO28 interaction and HIF-1α ubiquitination (glioblastoma); Co-IP of ICMT with RAS localization imaging (melanoma); Co-IP and phosphorylation/ubiquitin assays for PIM2-Thr140 (endometriosis)","pmids":["36115843","35914811","36109523"],"confidence":"Medium","gaps":["Whether PFKFB4 enzymatic activity is required for its interaction with FBXO28 or ICMT","Direct structural characterization of PFKFB4-ICMT or PFKFB4-FBXO28 complexes lacking","PIM2-Thr140 regulation not validated in cancer contexts"]},{"year":2022,"claim":"Discovery that hypoxia triggers PFKFB4 nuclear translocation where it non-canonically activates HIF-1α transcription established a feed-forward loop between HIF-1α (which transcribes PFKFB4) and nuclear PFKFB4 (which activates HIF-1α), linking metabolic enzyme subcellular redistribution to transcriptional rewiring.","evidence":"Nuclear fractionation, immunofluorescence, metabolomics, genetic ablation in breast cancer mouse models","pmids":["36476868"],"confidence":"Medium","gaps":["Nuclear translocation signal or mechanism not identified","Whether nuclear PFKFB4 directly binds the HIF-1α promoter or acts through an intermediary"]},{"year":2023,"claim":"Identification of FBXL7 as an E3 ligase that ubiquitinates and degrades PFKFB4, repressed by HIF-1α→EZH2 signaling, completed a regulatory circuit: HIF-1α stabilizes PFKFB4 both transcriptionally and post-translationally, while PFKFB4 in turn activates HIF-1α.","evidence":"TAP/MS substrate identification, ubiquitination assays, ChIP for EZH2-mediated FBXL7 repression in NSCLC","pmids":["37179372"],"confidence":"Medium","gaps":["Ubiquitination site(s) on PFKFB4 targeted by FBXL7 not mapped","Whether CHIP and FBXL7 target the same or different PFKFB4 pools"]},{"year":2025,"claim":"Identification of CHIP-mediated ubiquitination of PFKFB4 at K305, a splice variant (PFKFB4-ΔEx6) that directly binds and activates AKT, and PFKFB4 phosphorylation of HSPB1 to suppress ferroptosis broadened the post-translational regulatory landscape and substrate repertoire of PFKFB4.","evidence":"Co-IP and K305 mutagenesis for CHIP (endometriosis); IP and kinase assay for AKT-binding splice variant (HCC); Co-IP and ferroptosis assays for HSPB1 (gastric cancer)","pmids":["40684802","41281445","41577048"],"confidence":"Medium","gaps":["HSPB1 phosphorylation site not mapped","How the ΔEx6 deletion alters PFKFB4 structure to enable AKT binding is unknown","Whether K305 ubiquitination by CHIP competes with FBXL7 activity"]},{"year":null,"claim":"Major unresolved questions include the structural basis for PFKFB4's dual metabolic and protein kinase activities (whether the same active site catalyzes both), the signals governing nuclear translocation, how genetic context (e.g. TP53 status) switches kinase/phosphatase dominance, and whether the non-glycolytic developmental functions observed in Xenopus are conserved in mammalian development.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal structure of PFKFB4 in complex with a protein substrate","Nuclear localization signal not mapped","Kinase/phosphatase switch mechanism undefined","Mammalian developmental phenotypes untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1,2,9,10,24]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,10,24]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[1,18]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[7,8,20]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,2]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,12]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[1,2,18]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,4,8,20]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,12]}],"complexes":[],"partners":["SRC-3","SRC-2","ICMT","FBXO28","PIM2","FBXL7","CHIP","BMX"],"other_free_text":[]},"mechanistic_narrative":"PFKFB4 is a bifunctional 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase that integrates glycolytic control with non-metabolic signaling through its dual capacity as a metabolic enzyme and an atypical protein kinase. Its kinase activity predominates (~4-fold over phosphatase activity), synthesizing fructose-2,6-bisphosphate to allosterically activate PFK-1 and drive glycolytic flux, though in specific genetic contexts such as TP53-mutant hepatocellular carcinoma the phosphatase activity dominates [PMID:25115398, PMID:36806581]. Beyond canonical metabolic function, PFKFB4 acts as an atypical protein kinase that phosphorylates nuclear transcriptional coactivators SRC-3 (at Ser857) and SRC-2 (at Ser487), redirecting glucose flux toward the pentose phosphate pathway and purine synthesis via ATF4-dependent transcription, and also phosphorylates HSPB1 to suppress ferroptosis [PMID:29615789, PMID:33593309, PMID:41577048]. PFKFB4 additionally engages non-glycolytic signaling by interacting with ICMT to control RAS membrane localization and AKT activation, by translocating to the nucleus under hypoxia to activate HIF-1α transcription in a feed-forward loop with its own HIF-1α-driven expression, and by directly binding AKT through a splice variant (PFKFB4-ΔEx6) to activate AKT/mTOR signaling [PMID:35914811, PMID:36476868, PMID:41281445, PMID:25601028]."},"prefetch_data":{"uniprot":{"accession":"Q16877","full_name":"6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4","aliases":["6PF-2-K/Fru-2,6-P2ase testis-type isozyme"],"length_aa":469,"mass_kda":54.0,"function":"Synthesis and degradation of fructose 2,6-bisphosphate","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/Q16877/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PFKFB4","classification":"Not Classified","n_dependent_lines":25,"n_total_lines":1208,"dependency_fraction":0.020695364238410598},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PFKFB4","total_profiled":1310},"omim":[{"mim_id":"610775","title":"TP53-INDUCED GLYCOLYSIS AND APOPTOSIS REGULATOR; TIGAR","url":"https://www.omim.org/entry/610775"},{"mim_id":"605320","title":"6-@PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE 4; PFKFB4","url":"https://www.omim.org/entry/605320"},{"mim_id":"601937","title":"NUCLEAR RECEPTOR COACTIVATOR 3; NCOA3","url":"https://www.omim.org/entry/601937"},{"mim_id":"114480","title":"BREAST CANCER","url":"https://www.omim.org/entry/114480"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoli","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"testis","ntpm":23.8}],"url":"https://www.proteinatlas.org/search/PFKFB4"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q16877","domains":[{"cath_id":"3.40.50.300","chopping":"39-243","consensus_level":"high","plddt":92.9414,"start":39,"end":243},{"cath_id":"3.40.50.1240","chopping":"251-461","consensus_level":"high","plddt":96.2089,"start":251,"end":461}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16877","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q16877-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q16877-F1-predicted_aligned_error_v6.png","plddt_mean":92.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PFKFB4","jax_strain_url":"https://www.jax.org/strain/search?query=PFKFB4"},"sequence":{"accession":"Q16877","fasta_url":"https://rest.uniprot.org/uniprotkb/Q16877.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q16877/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16877"}},"corpus_meta":[{"pmid":"29615789","id":"PMC_29615789","title":"Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/29615789","citation_count":205,"is_preprint":false},{"pmid":"22056879","id":"PMC_22056879","title":"RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22056879","citation_count":118,"is_preprint":false},{"pmid":"33671514","id":"PMC_33671514","title":"Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33671514","citation_count":116,"is_preprint":false},{"pmid":"30613295","id":"PMC_30613295","title":"CD44ICD promotes breast cancer stemness via PFKFB4-mediated glucose metabolism.","date":"2018","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/30613295","citation_count":84,"is_preprint":false},{"pmid":"25115398","id":"PMC_25115398","title":"Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25115398","citation_count":73,"is_preprint":false},{"pmid":"29208667","id":"PMC_29208667","title":"Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy.","date":"2017","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29208667","citation_count":65,"is_preprint":false},{"pmid":"29029419","id":"PMC_29029419","title":"CD44 regulates prostate cancer proliferation, invasion and migration via PDK1 and PFKFB4.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29029419","citation_count":56,"is_preprint":false},{"pmid":"39570804","id":"PMC_39570804","title":"PTBP1 Lactylation Promotes Glioma Stem Cell Maintenance through PFKFB4-Driven Glycolysis.","date":"2025","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/39570804","citation_count":53,"is_preprint":false},{"pmid":"27181362","id":"PMC_27181362","title":"HIF-1α activates hypoxia-induced PFKFB4 expression in human bladder cancer cells.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27181362","citation_count":51,"is_preprint":false},{"pmid":"37500615","id":"PMC_37500615","title":"THOC3 interacts with YBX1 to promote lung squamous cell carcinoma progression through PFKFB4 mRNA modification.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37500615","citation_count":42,"is_preprint":false},{"pmid":"36109523","id":"PMC_36109523","title":"Phosphorylation of PFKFB4 by PIM2 promotes anaerobic glycolysis and cell proliferation in endometriosis.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36109523","citation_count":41,"is_preprint":false},{"pmid":"33803236","id":"PMC_33803236","title":"Carbonic Anhydrase IX Promotes Human Cervical Cancer Cell Motility by Regulating PFKFB4 Expression.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33803236","citation_count":40,"is_preprint":false},{"pmid":"26221874","id":"PMC_26221874","title":"Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26221874","citation_count":40,"is_preprint":false},{"pmid":"33992797","id":"PMC_33992797","title":"Bruceine A induces cell growth inhibition and apoptosis through PFKFB4/GSK3β signaling in pancreatic cancer.","date":"2021","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/33992797","citation_count":35,"is_preprint":false},{"pmid":"33774025","id":"PMC_33774025","title":"E2F2 drives glioma progression via PI3K/AKT in a PFKFB4-dependent manner.","date":"2021","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33774025","citation_count":34,"is_preprint":false},{"pmid":"34593007","id":"PMC_34593007","title":"PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance.","date":"2021","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/34593007","citation_count":34,"is_preprint":false},{"pmid":"27769068","id":"PMC_27769068","title":"Phosphorylation of PPARγ at Ser84 promotes glycolysis and cell proliferation in hepatocellular carcinoma by targeting PFKFB4.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27769068","citation_count":33,"is_preprint":false},{"pmid":"25601028","id":"PMC_25601028","title":"PFKFB4 controls embryonic patterning via Akt signalling independently of glycolysis.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25601028","citation_count":33,"is_preprint":false},{"pmid":"29038306","id":"PMC_29038306","title":"PFKFB4 control of AKT signaling is essential for premigratory and migratory neural crest formation.","date":"2017","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/29038306","citation_count":28,"is_preprint":false},{"pmid":"30415245","id":"PMC_30415245","title":"PFKFB4 Promotes Breast Cancer Metastasis via Induction of Hyaluronan Production in a p38-Dependent Manner.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30415245","citation_count":25,"is_preprint":false},{"pmid":"28152500","id":"PMC_28152500","title":"Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28152500","citation_count":24,"is_preprint":false},{"pmid":"36806581","id":"PMC_36806581","title":"PFKFB4 Drives the Oncogenicity in TP53-Mutated Hepatocellular Carcinoma in a Phosphatase-Dependent Manner.","date":"2023","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/36806581","citation_count":24,"is_preprint":false},{"pmid":"31912488","id":"PMC_31912488","title":"PFKFB4 negatively regulated the expression of histone acetyltransferase GCN5 to mediate the tumorigenesis of thyroid cancer.","date":"2020","source":"Development, growth & differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/31912488","citation_count":23,"is_preprint":false},{"pmid":"34970545","id":"PMC_34970545","title":"Long Non-Coding RNA LINC01572 Promotes Hepatocellular Carcinoma Progression via Sponging miR-195-5p to Enhance PFKFB4-Mediated Glycolysis and PI3K/AKT Activation.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34970545","citation_count":23,"is_preprint":false},{"pmid":"34093813","id":"PMC_34093813","title":"Long noncoding RNA FIRRE contributes to the proliferation and glycolysis of hepatocellular carcinoma cells by enhancing PFKFB4 expression.","date":"2021","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34093813","citation_count":22,"is_preprint":false},{"pmid":"33593309","id":"PMC_33593309","title":"PFKFB4 promotes lung adenocarcinoma progression via phosphorylating and activating transcriptional coactivator SRC-2.","date":"2021","source":"BMC pulmonary medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33593309","citation_count":21,"is_preprint":false},{"pmid":"36476868","id":"PMC_36476868","title":"Hypoxic activation of PFKFB4 in breast tumor microenvironment shapes metabolic and cellular plasticity to accentuate metastatic competence.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36476868","citation_count":21,"is_preprint":false},{"pmid":"22811469","id":"PMC_22811469","title":"Sertoli-secreted FGF-2 induces PFKFB4 isozyme expression in mouse spermatogenic cells by activation of the MEK/ERK/CREB pathway.","date":"2012","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22811469","citation_count":21,"is_preprint":false},{"pmid":"37179372","id":"PMC_37179372","title":"Hypoxia-mediated promotion of glucose metabolism in non-small cell lung cancer correlates with activation of the EZH2/FBXL7/PFKFB4 axis.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37179372","citation_count":17,"is_preprint":false},{"pmid":"36127291","id":"PMC_36127291","title":"PFKFB4 facilitates palbociclib resistance in oestrogen receptor-positive breast cancer by enhancing stemness.","date":"2022","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/36127291","citation_count":15,"is_preprint":false},{"pmid":"37222403","id":"PMC_37222403","title":"Reprogramming of glucose metabolism via PFKFB4 is critical in FGF16-driven invasion of breast cancer cells.","date":"2023","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/37222403","citation_count":15,"is_preprint":false},{"pmid":"35590288","id":"PMC_35590288","title":"KDM3A-mediated SP1 activates PFKFB4 transcription to promote aerobic glycolysis in osteosarcoma and augment tumor development.","date":"2022","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35590288","citation_count":15,"is_preprint":false},{"pmid":"34976184","id":"PMC_34976184","title":"PFKFB4 promotes angiogenesis via IL-6/STAT5A/P-STAT5 signaling in breast cancer.","date":"2022","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34976184","citation_count":15,"is_preprint":false},{"pmid":"32487245","id":"PMC_32487245","title":"The metabolic role of PFKFB4 in androgen-independent growth in vitro and PFKFB4 expression in human prostate cancer tissue.","date":"2020","source":"BMC urology","url":"https://pubmed.ncbi.nlm.nih.gov/32487245","citation_count":14,"is_preprint":false},{"pmid":"30504385","id":"PMC_30504385","title":"Analysis of Malignant Melanoma Cell Lines Exposed to Hypoxia Reveals the Importance of PFKFB4 Overexpression for Disease Progression.","date":"2018","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30504385","citation_count":13,"is_preprint":false},{"pmid":"31754349","id":"PMC_31754349","title":"The influence of PFK-II overexpression on neuroblastoma patients' survival may be dependent on the particular isoenzyme expressed, PFKFB3 or PFKFB4.","date":"2019","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/31754349","citation_count":13,"is_preprint":false},{"pmid":"40213972","id":"PMC_40213972","title":"Targeting PFKFB4 Biomimetic Codelivery System Synergistically Enhances Ferroptosis to Suppress Small Cell Lung Cancer and Augments the Efficacy of Anti-PD-L1 Immunotherapy.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/40213972","citation_count":12,"is_preprint":false},{"pmid":"36115843","id":"PMC_36115843","title":"PFKFB4 interacts with FBXO28 to promote HIF-1α signaling in glioblastoma.","date":"2022","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/36115843","citation_count":12,"is_preprint":false},{"pmid":"35578370","id":"PMC_35578370","title":"Therapeutic targeting of PFKFB3 and PFKFB4 in multiple myeloma cells under hypoxic conditions.","date":"2022","source":"Biomarker research","url":"https://pubmed.ncbi.nlm.nih.gov/35578370","citation_count":11,"is_preprint":false},{"pmid":"15642344","id":"PMC_15642344","title":"Specific expression of pfkfb4 gene in spermatogonia germ cells and analysis of its 5'-flanking region.","date":"2005","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/15642344","citation_count":11,"is_preprint":false},{"pmid":"35914811","id":"PMC_35914811","title":"PFKFB4 interacts with ICMT and activates RAS/AKT signaling-dependent cell migration in melanoma.","date":"2022","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/35914811","citation_count":10,"is_preprint":false},{"pmid":"40739397","id":"PMC_40739397","title":"Targeting the proliferation of glioblastoma cells and enhancement of doxorubicin and temozolomide cytotoxicity through inhibition of PFKFB4 and HMOX1 genes with siRNAs.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/40739397","citation_count":10,"is_preprint":false},{"pmid":"27614159","id":"PMC_27614159","title":"Pro-fibrotic effects of PFKFB4-mediated glycolytic reprogramming in fibrous dysplasia.","date":"2016","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/27614159","citation_count":9,"is_preprint":false},{"pmid":"35659173","id":"PMC_35659173","title":"Loss of PFKFB4 induces cell cycle arrest and glucose metabolism inhibition by inactivating MEK/ERK/c-Myc pathway in cervical cancer cells.","date":"2022","source":"Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology","url":"https://pubmed.ncbi.nlm.nih.gov/35659173","citation_count":9,"is_preprint":false},{"pmid":"39182558","id":"PMC_39182558","title":"Fibrillarin reprograms glucose metabolism by driving the enhancer-mediated transcription of PFKFB4 in liver cancer.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/39182558","citation_count":8,"is_preprint":false},{"pmid":"36034839","id":"PMC_36034839","title":"β-elemene Isopropanolamine Derivative LXX-8250 Induces Apoptosis Through Impairing Autophagic Flux via PFKFB4 Repression in Melanoma Cells.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36034839","citation_count":8,"is_preprint":false},{"pmid":"32299611","id":"PMC_32299611","title":"PFKFB4 is critical for the survival of acute monocytic leukemia cells.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32299611","citation_count":8,"is_preprint":false},{"pmid":"40339954","id":"PMC_40339954","title":"Glycolytic enzyme PFKFB4 governs lipolysis by promoting de novo lipogenesis to drive the progression of hepatocellular carcinoma.","date":"2025","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/40339954","citation_count":7,"is_preprint":false},{"pmid":"37770581","id":"PMC_37770581","title":"Differential roles of highly expressed PFKFB4 in colon adenocarcinoma patients.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/37770581","citation_count":7,"is_preprint":false},{"pmid":"40116122","id":"PMC_40116122","title":"PFKFB4 promotes endometrial cancer by regulating glycolysis through SRC‑3 phosphorylation.","date":"2025","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/40116122","citation_count":6,"is_preprint":false},{"pmid":"35926796","id":"PMC_35926796","title":"PFKFB4 modulated by miR-195-5p can boost the malignant progression of cervical cancer cells.","date":"2022","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/35926796","citation_count":6,"is_preprint":false},{"pmid":"39595571","id":"PMC_39595571","title":"Single-Cell RNA-Seq Analysis Links DNMT3B and PFKFB4 Transcriptional Profiles with Metastatic Traits in Hepatoblastoma.","date":"2024","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/39595571","citation_count":5,"is_preprint":false},{"pmid":"40091822","id":"PMC_40091822","title":"Kaempferol Induces DNA Damage in Colorectal Cancer Cells by Regulating the MiR-195/miR-497-PFKFB4-Mediated Nonoxidative Pentose Phosphate Pathway.","date":"2025","source":"Journal of agricultural and food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40091822","citation_count":4,"is_preprint":false},{"pmid":"39295558","id":"PMC_39295558","title":"Overexpression of SLC2A1, ALDOC, and PFKFB4 in the glycolysis pathway drives strong drug resistance in 3D HeLa tumor cell spheroids.","date":"2024","source":"Biotechnology journal","url":"https://pubmed.ncbi.nlm.nih.gov/39295558","citation_count":4,"is_preprint":false},{"pmid":"40274624","id":"PMC_40274624","title":"USP5 motivates immunosuppressive microenvironment in multiple myeloma by activating STAT2-PFKFB4-mediated glycolysis.","date":"2025","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/40274624","citation_count":3,"is_preprint":false},{"pmid":"40274346","id":"PMC_40274346","title":"Emd-D inhibited ovarian cancer progression via PFKFB4-dependent glycolysis and apoptosis.","date":"2025","source":"Chinese journal of natural medicines","url":"https://pubmed.ncbi.nlm.nih.gov/40274346","citation_count":3,"is_preprint":false},{"pmid":"39097893","id":"PMC_39097893","title":"MiR-3195 inhibits non-small cell lung cancer malignant behaviors along with cisplatin resistance through targeting PFKFB4.","date":"2024","source":"Cellular and molecular biology (Noisy-le-Grand, France)","url":"https://pubmed.ncbi.nlm.nih.gov/39097893","citation_count":3,"is_preprint":false},{"pmid":"40659958","id":"PMC_40659958","title":"Sulforaphane-cysteine inhibits α-tubulin/PD-L1/PFKFB4 axis leading to apoptosis in human glioblastoma.","date":"2025","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/40659958","citation_count":2,"is_preprint":false},{"pmid":"41411889","id":"PMC_41411889","title":"Bruceine A abrogates pancreatic cancer metastasis by suppressing PFKFB4-glycolysis-EMT axis.","date":"2025","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41411889","citation_count":1,"is_preprint":false},{"pmid":"36292148","id":"PMC_36292148","title":"Recessive Dystrophic Epidermolysis bullosa due to Hemizygous 40 kb Deletion of COL7A1 and the Proximate PFKFB4 Gene Focusing on the Mutation c.425A>G Mimicking Homozygous Status.","date":"2022","source":"Diagnostics (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/36292148","citation_count":1,"is_preprint":false},{"pmid":"41118116","id":"PMC_41118116","title":"Targeting phosphofructokinase 2 the isoform PFKFB4 suppresses glioblastoma proliferation and malignancy.","date":"2025","source":"Genes & genomics","url":"https://pubmed.ncbi.nlm.nih.gov/41118116","citation_count":0,"is_preprint":false},{"pmid":"40684802","id":"PMC_40684802","title":"Ubiquitination of PFKFB4 by CHIP regulates glycolysis and progression in endometriosis†.","date":"2025","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/40684802","citation_count":0,"is_preprint":false},{"pmid":"41510091","id":"PMC_41510091","title":"5MPN effectively targets PFKFB4 and inhibits the glucose metabolism process and invasion of glioblastoma.","date":"2025","source":"Translational cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/41510091","citation_count":0,"is_preprint":false},{"pmid":"41579989","id":"PMC_41579989","title":"RBM15/IGF2BP3 promotes immune escape in bladder cancer by enhancing m6A modification of PFKFB4.","date":"2026","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/41579989","citation_count":0,"is_preprint":false},{"pmid":"38992762","id":"PMC_38992762","title":"Multi-omics analysis reveals that Cas13d contributes to PI3K-AKT signaling and facilitates cell proliferation via PFKFB4 upregulation.","date":"2024","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/38992762","citation_count":0,"is_preprint":false},{"pmid":"40925147","id":"PMC_40925147","title":"Structure-guided discovery of nitrobenzo-2-oxa-1,3-diazole (NBD) scaffold-based PFKFB4 inhibitors for cancer therapy.","date":"2025","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40925147","citation_count":0,"is_preprint":false},{"pmid":"41281445","id":"PMC_41281445","title":"Non-canonical splice variant of PFKFB4 in hepatocellular carcinoma activates AKT through direct interaction.","date":"2025","source":"JHEP reports : innovation in hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/41281445","citation_count":0,"is_preprint":false},{"pmid":"39835559","id":"PMC_39835559","title":"siRNA Knocking Down in HepG2 Cells Identifies PFKFB4 and HNF4α as Key Genes Important for Cancer Cell Survival.","date":"2025","source":"Current gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/39835559","citation_count":0,"is_preprint":false},{"pmid":"41750620","id":"PMC_41750620","title":"Proteomic Identification of PFKFB3 and PFKFB4 Associated with Coenzyme Metabolism and Redox Imbalance in Dairy Cows with Clinical Mastitis.","date":"2026","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/41750620","citation_count":0,"is_preprint":false},{"pmid":"41577048","id":"PMC_41577048","title":"PFKFB4-Mediated HSPB1 phosphorylation suppresses ferroptosis to Promote gastric cancer progression.","date":"2026","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41577048","citation_count":0,"is_preprint":false},{"pmid":"40563546","id":"PMC_40563546","title":"Correction: Desterke et al. Single-Cell RNA-Seq Analysis Links DNMT3B and PFKFB4 Transcriptional Profiles with Metastatic Traits in Hepatoblastoma. Biomolecules 2024, 14, 1394.","date":"2025","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/40563546","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.09.06.674616","title":"Zebrafish Xenografts Reveal a Context-dependent Role of PFKFB4 in Melanoma Cell","date":"2025-09-10","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.06.674616","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":38647,"output_tokens":6784,"usd":0.108851},"stage2":{"model":"claude-opus-4-6","input_tokens":10505,"output_tokens":4137,"usd":0.233925},"total_usd":0.342776,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2018,\n      \"finding\": \"PFKFB4 phosphorylates the transcriptional coactivator SRC-3 at serine 857, enhancing SRC-3 transcriptional activity. Phospho-Ser857 SRC-3 increases its interaction with transcription factor ATF4, stabilizing recruitment of SRC-3 and ATF4 to target gene promoters. This drives glucose flux toward the pentose phosphate pathway and enables purine synthesis by transcriptionally upregulating transketolase, AMPD1, and XDH.\",\n      \"method\": \"Kinome-wide RNAi screen, in vitro kinase assay, phosphorylation-deficient mutant (Ser857Ala), Co-IP, ChIP, orthotopic xenograft mouse model\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including in vitro kinase assay, mutagenesis, Co-IP, ChIP, and in vivo validation in a single rigorous study\",\n      \"pmids\": [\"29615789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Recombinant human PFKFB4 exhibits kinase activity 4.3-fold greater than its phosphatase activity, functioning primarily to synthesize fructose-2,6-bisphosphate (F2,6BP), which allosterically activates PFK-1 to increase glycolytic flux. siRNA and genomic deletion of PFKFB4 decrease F2,6BP levels, while overexpression increases them.\",\n      \"method\": \"In vitro enzymatic assay with recombinant human PFKFB4, siRNA knockdown, genomic deletion, metabolite measurement (F2,6BP, glucose uptake, ATP)\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro kinase/phosphatase assay with recombinant protein, corroborated by genetic loss- and gain-of-function\",\n      \"pmids\": [\"25115398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"A first-in-class PFKFB4 inhibitor (5MPN), identified by structure-based virtual screening, selectively inhibits PFKFB4 kinase activity, suppresses intracellular F2,6BP synthesis, reduces glycolysis, and inhibits tumor growth in mice upon oral administration.\",\n      \"method\": \"Structure-based virtual computational screening, in vitro enzyme inhibition assay, cell proliferation assays, in vivo xenograft mouse model\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — structure-guided inhibitor design with in vitro enzymatic validation and in vivo efficacy\",\n      \"pmids\": [\"26221874\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In Xenopus (frog) embryos, PFKFB4 controls dorsal ectoderm patterning and progenitor differentiation via a non-glycolytic function mediated by AKT signaling. Restoring AKT signaling rescues the PFKFB4 loss-of-function phenotype, while glycolysis inhibition does not recapitulate the patterning defects.\",\n      \"method\": \"Loss-of-function morpholino depletion in Xenopus embryos, epistasis rescue with constitutively active AKT, glycolysis inhibitors as controls\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo with multiple rescue conditions demonstrating AKT dependence and glycolysis independence\",\n      \"pmids\": [\"25601028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PFKFB4 is essential for neural crest (NC) specification and migration in Xenopus embryos. PFKFB4 controls AKT signaling during late NC specification, while both AKT signaling and glycolysis regulate NC migration. NC gene regulatory network drives pfkfb4 upregulation during NC specification.\",\n      \"method\": \"Time-controlled and hypomorph depletions in vivo (Xenopus), AKT signaling rescue, glycolysis inhibition experiments\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with multiple conditions, in vivo phenotypic rescue\",\n      \"pmids\": [\"29038306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Etk (BMX) tyrosine kinase directly interacts with PFKFB4 (identified by co-IP and GST pulldown), and PFKFB4 is a downstream target of Etk that promotes chemoresistance in small-cell lung cancer through regulation of autophagy.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, microarray analysis, gain/loss-of-function in vitro and in vivo, PDX model\",\n      \"journal\": \"Clinical Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP and GST pulldown confirm direct interaction; functional link to autophagy established\",\n      \"pmids\": [\"29208667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PIM2 kinase phosphorylates PFKFB4 at threonine 140 (Thr140), enhancing PFKFB4 protein stability via the ubiquitin-proteasome pathway and promoting glycolysis and cell growth in endometriosis. PIM2 was identified as a binding partner of PFKFB4.\",\n      \"method\": \"Co-IP, biochemical phosphorylation assays, ubiquitin-proteasome pathway analysis, in vivo endometriosis model\",\n      \"journal\": \"Cell Death & Disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — site-specific phosphorylation identified biochemically with functional validation\",\n      \"pmids\": [\"36109523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PFKFB4 interacts with the E3 ubiquitin ligase FBXO28, and this interaction regulates ubiquitylation and proteasomal degradation of HIF-1α in glioblastoma. PFKFB4 silencing dramatically reduces HIF protein levels and hypoxia-related gene expression.\",\n      \"method\": \"Mass spectrometric analysis of immunoprecipitated PFKFB4 (identifying FBXO28), Western blot, gene expression profiling, orthotopic patient-derived mouse model\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — MS-identified interaction partner with functional validation of HIF-1α ubiquitination\",\n      \"pmids\": [\"36115843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PFKFB4 interacts with ICMT (a posttranslational modifier of RAS), promotes ICMT/RAS interaction, controls RAS localization at the plasma membrane, activates AKT signaling, and enhances melanoma cell migration independently of glycolysis.\",\n      \"method\": \"Co-IP, RAS localization imaging, AKT signaling assays, migration assays with PFKFB4 loss-of-function\",\n      \"journal\": \"Life Science Alliance\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP demonstrating interaction, supported by functional rescue experiments and localization data\",\n      \"pmids\": [\"35914811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PFKFB4 phosphorylates NCOA3 (SRC-3/AIB1) in clear-cell renal cell carcinoma, and this phosphorylated NCOA3 interacts with FBP1 to counteract overactive pentose phosphate pathway flux, forming a regulatory loop. PFKFB4 also promotes the pentose phosphate pathway in ccRCC.\",\n      \"method\": \"Phosphoproteomics, immunoprecipitation, metabolomics, CRISPR/Cas9 knockout\",\n      \"journal\": \"Journal of Experimental & Clinical Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — phosphoproteomics and immunoprecipitation with metabolomic validation\",\n      \"pmids\": [\"34593007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PFKFB4 promotes lung adenocarcinoma progression by phosphorylating SRC-2 (steroid receptor coactivator-2) at Ser487, altering its transcriptional activity, which transcriptionally upregulates CARM1.\",\n      \"method\": \"Co-immunoprecipitation, Western blot for phosphorylation, PFKFB4 knockdown, transcriptome sequencing\",\n      \"journal\": \"BMC Pulmonary Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP and phosphorylation analysis with downstream transcriptome validation\",\n      \"pmids\": [\"33593309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PFKFB4 promotes breast cancer metastasis via induction of HAS2 expression and hyaluronan (HA) production in a p38 signaling-dependent manner. PFKFB4 loss-of-function reduces HAS2 mRNA/protein and HA secretion.\",\n      \"method\": \"Gain- and loss-of-function assays, ELISA, immunofluorescence, orthotopic xenograft, experimental metastasis model\",\n      \"journal\": \"Cellular Physiology and Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo functional studies with defined downstream pathway (p38/HAS2)\",\n      \"pmids\": [\"30415245\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Hypoxic induction of PFKFB4 triggers its nuclear translocation, where it non-canonically activates HIF-1α transcription, creating a feed-forward loop. Breast cancer patients with increased nuclear PFKFB4 correlate with poor prognosis.\",\n      \"method\": \"Photoacoustic imaging, metabolomics, genetic ablation in mouse models, nuclear fractionation/immunofluorescence localization, gene expression analysis\",\n      \"journal\": \"Cell Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiment (nuclear translocation) linked to functional consequence (HIF-1α activation), supported by in vivo genetic ablation\",\n      \"pmids\": [\"36476868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FBXL7 (an E3 ubiquitin ligase) ubiquitinates and degrades PFKFB4 protein, suppressing glucose metabolism. Hypoxia-induced HIF-1α upregulates EZH2, which represses FBXL7 transcription, thereby stabilizing PFKFB4 and promoting glycolysis in NSCLC. PFKFB4 was identified as an FBXL7 substrate by tandem affinity purification/mass spectrometry.\",\n      \"method\": \"Tandem affinity purification coupled with mass spectrometry (TAP/MS), ubiquitination assay, ChIP, loss-of-function, rescue experiments\",\n      \"journal\": \"Cell Death & Disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — substrate identified by TAP/MS with functional ubiquitination validation\",\n      \"pmids\": [\"37179372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"THOC3 forms a complex with YBX1 to promote PFKFB4 transcription and is responsible for exporting PFKFB4 mRNA to the cytoplasm; YBX1 ensures stability of PFKFB4 mRNA by recognizing m5C sites in its 3'UTR.\",\n      \"method\": \"Co-IP, mRNA export assays, YBX1-m5C binding analysis, knockdown functional assays\",\n      \"journal\": \"Cell Death & Disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP for complex formation with mechanistic mRNA regulation assays\",\n      \"pmids\": [\"37500615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"HIF-1α directly transactivates PFKFB4 expression in bladder cancer under hypoxia by binding to a specific hypoxia-responsive element (HRE-D) in the PFKFB4 promoter, as identified by deletion constructs and double-immunofluorescence co-localization.\",\n      \"method\": \"Promoter deletion/luciferase assays, ChIP, double-immunofluorescence co-localization, hypoxia exposure\",\n      \"journal\": \"Biochemical and Biophysical Research Communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter-reporter assays with mutagenesis identifying functional HRE, supported by ChIP\",\n      \"pmids\": [\"27181362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Phosphorylation of PPARγ at Ser84 (by MEK/ERK) drives PFKFB4 expression by directly modulating its promoter transcriptional activity, as shown by ChIP. PFKFB4 is required for the PPARγ phosphorylation-mediated stimulation of glycolysis and proliferation in hepatocellular carcinoma.\",\n      \"method\": \"RNA microarray, ChIP assay, PFKFB4 knockdown rescue experiments, HCC mouse model\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirms direct promoter binding, PFKFB4 knockdown establishes epistasis\",\n      \"pmids\": [\"27769068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Sertoli cell-secreted FGF-2 induces PFKFB4 expression in mouse spermatogenic cells via the MEK/ERK/CREB pathway. A CRE-binding sequence at -1,463 relative to the transcription start site is required for PFKFB4 gene activation. CREB transcription factor binding to this site was confirmed by pulldown assays.\",\n      \"method\": \"Conditioned medium experiments, MAPK inhibitor panel, luciferase analysis of promoter deletion constructs, CREB pulldown assay, anti-FGF-2 neutralizing antibodies\",\n      \"journal\": \"American Journal of Physiology – Endocrinology and Metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter-reporter assays with mutagenesis and CREB pulldown identifying functional CRE site\",\n      \"pmids\": [\"22811469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In hepatocellular carcinoma with TP53 loss-of-function mutations, PFKFB4 functions predominantly as a phosphatase (not kinase); its ablation causes accumulation of metabolites in downstream glycolysis and the pentose phosphate pathway, and also induces hypoxia-responsive genes in glycolysis and ROS detoxification.\",\n      \"method\": \"CRISPR/Cas9 knockout, targeted metabolomic profiling, RNA sequencing, in vivo HCC model\",\n      \"journal\": \"Cellular and Molecular Gastroenterology and Hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR KO with metabolomic profiling providing direct mechanistic evidence of phosphatase activity dominance in this context\",\n      \"pmids\": [\"36806581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The E3 ubiquitin ligase CHIP directly binds and ubiquitinates PFKFB4 at lysine 305 (K305), promoting its proteasomal degradation and suppressing glycolysis and invasiveness in endometriosis cells.\",\n      \"method\": \"Co-IP, ubiquitination assay, site-directed mutagenesis (K305), in vitro and in vivo endometriosis models\",\n      \"journal\": \"Biology of Reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — site-specific ubiquitination site identified by mutagenesis with functional validation\",\n      \"pmids\": [\"40684802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"A non-canonical splice variant of PFKFB4 (PFKFB4-ΔEx6, skipping exon 6, resulting in a 19-amino acid in-frame deletion) directly binds the kinase domain of AKT and activates AKT/mTOR signaling in hepatocellular carcinoma, promoting HCC proliferation and tumorigenicity more potently than canonical PFKFB4.\",\n      \"method\": \"Protein immunoprecipitation, in vitro kinase assay, Human Phospho-Kinase Array profiling, HCC cell line and xenograft models\",\n      \"journal\": \"JHEP Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro kinase assay and immunoprecipitation demonstrating direct binding to AKT kinase domain\",\n      \"pmids\": [\"41281445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MLL (a histone methyltransferase/epigenetic regulator) promotes PFKFB4 expression at the transcriptional level through the putative E2F6 binding site in the pfkfb4 gene promoter in acute monocytic leukemia cells.\",\n      \"method\": \"ChIP, promoter analysis, PFKFB4 knockdown/inhibitor functional assays\",\n      \"journal\": \"Biochemical and Biophysical Research Communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — ChIP-based promoter analysis without full mechanistic dissection; single study\",\n      \"pmids\": [\"32299611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PFKFB4-mediated glycolytic reprogramming activates pro-fibrotic TGFβ signaling in fibrous dysplasia. Depletion of PFKFB4 blocks fibrosis progression in GNAS(R201H)-mutated iPSC-derived mesenchymal stem cells.\",\n      \"method\": \"iPSC-derived FD disease models (2D and 3D), PFKFB4 depletion, glycolysis and TGFβ signaling inhibition experiments\",\n      \"journal\": \"Biomaterials\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — loss-of-function with pathway read-out, single study with no direct molecular mechanism for PFKFB4-TGFβ connection\",\n      \"pmids\": [\"27614159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"E2F2 transcriptionally activates PFKFB4 by directly binding to its promoter (shown by ChIP and luciferase assays), and PFKFB4 activates the PI3K/AKT pathway to promote glioma glycolysis and metastasis.\",\n      \"method\": \"ChIP, luciferase reporter assays, PFKFB4 knockdown rescue, PI3K/AKT pathway analysis\",\n      \"journal\": \"Life Sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — ChIP and reporter assays; epistasis for PI3K/AKT activation is inferred rather than directly demonstrated\",\n      \"pmids\": [\"33774025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PFKFB4 directly interacts with and phosphorylates HSPB1 (Heat Shock Protein Beta-1), suppressing ferroptosis and promoting gastric cancer progression. Pharmacological inhibition of PFKFB4 with 5MPN sensitizes gastric cancer cells to ferroptotic death.\",\n      \"method\": \"Co-IP, in vitro kinase assay (implied by 'direct interaction with and phosphorylation of HSPB1'), ferroptosis assays, 5MPN inhibitor treatment in vivo\",\n      \"journal\": \"Biochemical Pharmacology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single study; phosphorylation of HSPB1 described but full kinase assay methodology details limited in abstract\",\n      \"pmids\": [\"41577048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CD44ICD (the cleaved intracellular domain of CD44) interacts with CREB and binds to the PFKFB4 promoter, thereby regulating PFKFB4 transcription and expression, which in turn facilitates glycolysis and promotes breast cancer stemness.\",\n      \"method\": \"ChIP (CD44ICD-CREB-PFKFB4 promoter binding), gain/loss-of-function, glycolysis assays, stemness assays, xenograft model\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — ChIP for promoter occupancy; PFKFB4 role downstream is established functionally but mechanism of PFKFB4 action not dissected\",\n      \"pmids\": [\"30613295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In zebrafish larval xenografts, PFKFB4 depletion reduces invasion in MeWo melanoma cells (associated with reduced SNAIL2 expression) without affecting tumor growth, while in A375P cells it decreases tumor growth without affecting invasion—demonstrating context-dependent roles of PFKFB4 in melanoma progression.\",\n      \"method\": \"Zebrafish larval xenograft model, PFKFB4 depletion, SNAIL2 expression analysis, rescue experiments\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — in vivo loss-of-function in zebrafish model; preprint, single study\",\n      \"pmids\": [\"bio_10.1101_2025.09.06.674616\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PTBP1 lactylation (at K436) inhibits PTBP1 proteasomal degradation by attenuating its interaction with TRIM21, and lactylated PTBP1 enhances RNA-binding capacity and facilitates PFKFB4 mRNA stabilization, further increasing glycolysis in glioma stem cells. SIRT1 induces PTBP1 delactylation.\",\n      \"method\": \"Lactylation proteomics, co-IP, RNA-binding assays, PFKFB4 mRNA stability assays, PTBP1 K436 site-specific mutagenesis\",\n      \"journal\": \"Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — site-specific lactylation mutagenesis with RNA-binding and protein stability functional validation\",\n      \"pmids\": [\"39570804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PFKFB4 suppresses phosphorylated AMPK (p-AMPK) activity through enhanced aerobic glycolysis, which in turn stimulates SREBP1 expression, driving de novo lipid synthesis and promoting HCC proliferation.\",\n      \"method\": \"Functional assays (glycolysis and lipid synthesis), PFKFB4 knockdown/overexpression, AMPK and SREBP1 signaling pathway analysis\",\n      \"journal\": \"Cancer Letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — pathway inference from loss/gain-of-function without direct enzymatic demonstration of AMPK regulation\",\n      \"pmids\": [\"40339954\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PFKFB4 is a bifunctional enzyme (primarily acting as a kinase, with ~4-fold greater kinase than phosphatase activity in most cancer contexts) that synthesizes fructose-2,6-bisphosphate to allosterically activate PFK-1 and increase glycolytic flux; beyond this canonical metabolic role, PFKFB4 functions as an atypical protein kinase that phosphorylates nuclear transcriptional coactivators SRC-3 (at Ser857, promoting ATF4 interaction and pentose phosphate pathway gene transcription) and SRC-2 (at Ser487), can translocate to the nucleus to non-canonically activate HIF-1α transcription, interacts with FBXO28 to regulate HIF-1α ubiquitination, interacts with ICMT to control RAS membrane localization and AKT signaling, is regulated post-translationally by PIM2-mediated phosphorylation (Thr140) and CHIP/FBXL7-mediated ubiquitination, and controls AKT signaling (partly independently of glycolysis) during embryonic patterning and neural crest development.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PFKFB4 is a bifunctional 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase that integrates glycolytic control with non-metabolic signaling through its dual capacity as a metabolic enzyme and an atypical protein kinase. Its kinase activity predominates (~4-fold over phosphatase activity), synthesizing fructose-2,6-bisphosphate to allosterically activate PFK-1 and drive glycolytic flux, though in specific genetic contexts such as TP53-mutant hepatocellular carcinoma the phosphatase activity dominates [PMID:25115398, PMID:36806581]. Beyond canonical metabolic function, PFKFB4 acts as an atypical protein kinase that phosphorylates nuclear transcriptional coactivators SRC-3 (at Ser857) and SRC-2 (at Ser487), redirecting glucose flux toward the pentose phosphate pathway and purine synthesis via ATF4-dependent transcription, and also phosphorylates HSPB1 to suppress ferroptosis [PMID:29615789, PMID:33593309, PMID:41577048]. PFKFB4 additionally engages non-glycolytic signaling by interacting with ICMT to control RAS membrane localization and AKT activation, by translocating to the nucleus under hypoxia to activate HIF-1α transcription in a feed-forward loop with its own HIF-1α-driven expression, and by directly binding AKT through a splice variant (PFKFB4-ΔEx6) to activate AKT/mTOR signaling [PMID:35914811, PMID:36476868, PMID:41281445, PMID:25601028].\",\n  \"teleology\": [\n    {\n      \"year\": 2012,\n      \"claim\": \"Identifying how PFKFB4 transcription is controlled established the FGF-2/MEK/ERK/CREB axis as an upstream activating pathway, with a functional CRE site at −1,463 in the promoter, linking extracellular growth factor signaling to glycolytic gene regulation in spermatogenic cells.\",\n      \"evidence\": \"Conditioned medium, MAPK inhibitor panel, promoter deletion/luciferase assays, and CREB pulldown in mouse spermatogenic cells\",\n      \"pmids\": [\"22811469\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CREB-dependent activation operates in somatic/cancer cell contexts\", \"No chromatin-level mechanism described\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Resolving the long-debated kinase-versus-phosphatase balance for human PFKFB4 demonstrated that recombinant PFKFB4 functions primarily as a kinase (4.3-fold kinase > phosphatase), synthesizing F2,6BP to activate PFK-1 and glycolytic flux — establishing the canonical enzymatic function.\",\n      \"evidence\": \"In vitro enzymatic assay with recombinant protein, siRNA knockdown, genomic deletion, and F2,6BP/glucose/ATP measurement in cancer cells\",\n      \"pmids\": [\"25115398\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether kinase/phosphatase ratio varies across tissues or genetic backgrounds\", \"No structural basis for the kinase-dominant activity\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Discovery of a glycolysis-independent developmental role established that PFKFB4 controls dorsal ectoderm patterning via AKT signaling in Xenopus embryos, revealing that PFKFB4 has non-metabolic functions that cannot be explained by F2,6BP synthesis alone.\",\n      \"evidence\": \"Morpholino depletion in Xenopus embryos with epistasis rescue by constitutively active AKT; glycolysis inhibitors failed to phenocopy\",\n      \"pmids\": [\"25601028\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism linking PFKFB4 to AKT activation unknown at this point\", \"Whether the non-glycolytic function is conserved in mammals\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Development of a first-in-class selective PFKFB4 kinase inhibitor (5MPN) provided pharmacological proof that PFKFB4 kinase activity drives F2,6BP production and tumor growth, and delivered a chemical tool for functional studies.\",\n      \"evidence\": \"Structure-based virtual screening, in vitro enzyme inhibition, and oral xenograft efficacy in mice\",\n      \"pmids\": [\"26221874\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selectivity over other PFKFB family members not fully resolved\", \"No co-crystal structure reported\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identification of HIF-1α binding to a specific HRE (HRE-D) in the PFKFB4 promoter, and separately of phospho-PPARγ-driven PFKFB4 transcription, established that multiple hypoxia and oncogenic transcription factors directly induce PFKFB4 expression, explaining its upregulation across diverse cancers.\",\n      \"evidence\": \"Promoter deletion/luciferase and ChIP in bladder cancer (HIF-1α); ChIP and knockdown rescue in HCC (PPARγ)\",\n      \"pmids\": [\"27181362\", \"27769068\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How multiple transcription factors coordinate at the PFKFB4 promoter\", \"Relative contribution of each factor in different tumor types unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrating that PFKFB4 is essential for neural crest specification and migration through AKT signaling extended the non-glycolytic paradigm to a specific developmental cell type, while showing that glycolysis is separately required for NC migration.\",\n      \"evidence\": \"Time-controlled and hypomorph depletions with AKT rescue and glycolysis inhibition in Xenopus NC cells\",\n      \"pmids\": [\"29038306\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct PFKFB4-AKT biochemical interaction not demonstrated in this system\", \"Mammalian NC relevance untested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identification of Etk/BMX tyrosine kinase as a direct PFKFB4-binding partner linked PFKFB4 to chemoresistance via autophagy regulation in small-cell lung cancer, broadening its signaling network beyond AKT.\",\n      \"evidence\": \"Reciprocal co-IP, GST pulldown, microarray, PDX model in SCLC\",\n      \"pmids\": [\"29208667\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Etk phosphorylates PFKFB4 and at which site is unknown\", \"Autophagy mechanism downstream of PFKFB4 not dissected\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The pivotal discovery that PFKFB4 acts as an atypical protein kinase phosphorylating SRC-3 at Ser857 revealed a fundamentally new non-metabolic function: PFKFB4-mediated SRC-3 phosphorylation promotes SRC-3–ATF4 interaction, driving pentose phosphate pathway gene transcription and purine synthesis, thus redirecting glucose carbon beyond glycolysis.\",\n      \"evidence\": \"Kinome-wide RNAi screen, in vitro kinase assay, Ser857Ala mutagenesis, Co-IP, ChIP, orthotopic xenograft in breast cancer\",\n      \"pmids\": [\"29615789\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for PFKFB4's protein kinase activity versus its metabolic kinase activity unknown\", \"Whether PFKFB4 protein kinase activity uses the same active site as F6P phosphorylation\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Extension of the atypical kinase paradigm showed PFKFB4 phosphorylates SRC-2 at Ser487 (upregulating CARM1 transcription) and that phospho-SRC-3 interacts with FBP1 to form a regulatory feedback loop controlling pentose phosphate pathway flux in ccRCC, demonstrating substrate diversification.\",\n      \"evidence\": \"Co-IP and phosphorylation analysis with transcriptome sequencing (SRC-2, lung adenocarcinoma); phosphoproteomics and metabolomics with CRISPR KO (SRC-3/FBP1, ccRCC)\",\n      \"pmids\": [\"33593309\", \"34593007\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro kinase assay for SRC-2 not explicitly shown\", \"Whether SRC-2 and SRC-3 phosphorylation occur simultaneously in the same cells\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstration that PFKFB4 phosphatase activity predominates in TP53-mutant HCC — opposite to the canonical kinase-dominant model — revealed that the kinase/phosphatase balance is genetically context-dependent, with TP53 status switching PFKFB4's functional output.\",\n      \"evidence\": \"CRISPR/Cas9 knockout with targeted metabolomics and RNA-seq in TP53-mutant HCC\",\n      \"pmids\": [\"36806581\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism by which p53 loss shifts kinase/phosphatase ratio unknown\", \"Whether this applies to other p53-mutant cancer types\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Three concurrent discoveries expanded PFKFB4's non-metabolic signaling network: (1) PFKFB4 interacts with FBXO28 to regulate HIF-1α ubiquitination and stability, (2) PFKFB4 interacts with ICMT to promote RAS membrane localization and AKT activation independently of glycolysis, and (3) PIM2 phosphorylates PFKFB4 at Thr140 to stabilize it against proteasomal degradation — collectively revealing PFKFB4 as a signaling hub regulated by and regulating multiple oncogenic pathways.\",\n      \"evidence\": \"MS-identified FBXO28 interaction and HIF-1α ubiquitination (glioblastoma); Co-IP of ICMT with RAS localization imaging (melanoma); Co-IP and phosphorylation/ubiquitin assays for PIM2-Thr140 (endometriosis)\",\n      \"pmids\": [\"36115843\", \"35914811\", \"36109523\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PFKFB4 enzymatic activity is required for its interaction with FBXO28 or ICMT\", \"Direct structural characterization of PFKFB4-ICMT or PFKFB4-FBXO28 complexes lacking\", \"PIM2-Thr140 regulation not validated in cancer contexts\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Discovery that hypoxia triggers PFKFB4 nuclear translocation where it non-canonically activates HIF-1α transcription established a feed-forward loop between HIF-1α (which transcribes PFKFB4) and nuclear PFKFB4 (which activates HIF-1α), linking metabolic enzyme subcellular redistribution to transcriptional rewiring.\",\n      \"evidence\": \"Nuclear fractionation, immunofluorescence, metabolomics, genetic ablation in breast cancer mouse models\",\n      \"pmids\": [\"36476868\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Nuclear translocation signal or mechanism not identified\", \"Whether nuclear PFKFB4 directly binds the HIF-1α promoter or acts through an intermediary\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identification of FBXL7 as an E3 ligase that ubiquitinates and degrades PFKFB4, repressed by HIF-1α→EZH2 signaling, completed a regulatory circuit: HIF-1α stabilizes PFKFB4 both transcriptionally and post-translationally, while PFKFB4 in turn activates HIF-1α.\",\n      \"evidence\": \"TAP/MS substrate identification, ubiquitination assays, ChIP for EZH2-mediated FBXL7 repression in NSCLC\",\n      \"pmids\": [\"37179372\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitination site(s) on PFKFB4 targeted by FBXL7 not mapped\", \"Whether CHIP and FBXL7 target the same or different PFKFB4 pools\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identification of CHIP-mediated ubiquitination of PFKFB4 at K305, a splice variant (PFKFB4-ΔEx6) that directly binds and activates AKT, and PFKFB4 phosphorylation of HSPB1 to suppress ferroptosis broadened the post-translational regulatory landscape and substrate repertoire of PFKFB4.\",\n      \"evidence\": \"Co-IP and K305 mutagenesis for CHIP (endometriosis); IP and kinase assay for AKT-binding splice variant (HCC); Co-IP and ferroptosis assays for HSPB1 (gastric cancer)\",\n      \"pmids\": [\"40684802\", \"41281445\", \"41577048\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"HSPB1 phosphorylation site not mapped\", \"How the ΔEx6 deletion alters PFKFB4 structure to enable AKT binding is unknown\", \"Whether K305 ubiquitination by CHIP competes with FBXL7 activity\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major unresolved questions include the structural basis for PFKFB4's dual metabolic and protein kinase activities (whether the same active site catalyzes both), the signals governing nuclear translocation, how genetic context (e.g. TP53 status) switches kinase/phosphatase dominance, and whether the non-glycolytic developmental functions observed in Xenopus are conserved in mammalian development.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal structure of PFKFB4 in complex with a protein substrate\", \"Nuclear localization signal not mapped\", \"Kinase/phosphatase switch mechanism undefined\", \"Mammalian developmental phenotypes untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1, 2, 9, 10, 24]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 10, 24]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [1, 18]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [7, 8, 20]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 2]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [1, 2, 18]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 4, 8, 20]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 12]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"SRC-3\",\n      \"SRC-2\",\n      \"ICMT\",\n      \"FBXO28\",\n      \"PIM2\",\n      \"FBXL7\",\n      \"CHIP\",\n      \"BMX\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}